We identify an association of MUC17, SYNE1, and TENM1 mutations with prolonged survival; increased expression of CD68 in male glioblastoma patients; decreased OS with increased EGFR mRNA expression z-score, but not EGFR amplification or mutation; 14 transcripts upregulated in LTS patients; and 2 transcripts (TMBIM1 and CLSTN1) upregulated in STS patients. This evidence concerns the gene EGFR and glioblastoma.